Read the July/August edition of Pharmafocus online now!
pharmafile | June 28, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | NHS, Orkambi, Trump, UK, brexit, generics, manufacturing compliance, pharma
The latest monthly edition of Pharmafocus, the July/August issue, is available to read for free online now!
The UK remains split right down the middle as the Brexit crisis rolls on and on, and while we have been side-tracked from one political wedge to focus on another – the race to become the new leader of the Conservative Party, and, ultimately, the next Prime Minister – there is still one issue that never fails to heal the divide: the defence of the NHS.
This was proven once again earlier in June, when American Ambassador to the UK and Johnson & Johnson heir Woody Johnson’s suggestion that the health service could be “on the table” in post-Brexit trade negotiations was met with scorn on both sides of the aisle. You can read the full story on our front page this month.
Elsewhere in the UK, the Orkambi access dispute continues as Vertex and NHS England squabble over the availability of the cystic fibrosis drug. Patients are now taking the matter into their own hands with the establishment of a ‘Buyers’ club’, hoping to import generic versions of the medicine from Argentina. You can read the full details on page 5, with exclusive comment from Nick Medhurst, Head of Policy and Public Affairs at the Cystic Fibrosis Trust.
On a global scale, news has broken that 2018 was a record-breaking year for cancer drug launces, with more successfully hitting markets than any previous year. However, reports indicate, as if it wasn’t threatening enough, that climate change could fuel the spread of dengue fever into previously safe regions of the world. You can check out more on pages 7 and 8.
We also have full length features on manufacturing compliance – where Louis Goss quizzes investigative journalist Katherine Eban on her book Bottle of Lies, and its shocking findings on the generic drug industry – and patient-reported outcomes measures, where Matt Fellows examines how effective the use of such measures is in meeting the needs of today’s patients.
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
Five Facts about NHS and primary care
1 Primary care is the front door to the NHS, but it extends well beyond …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
